Reducing the Cost of Prescription Drugs and Health Care

Too many Americans cannot afford their prescription drugs, with some having to decide between prescription medicine and putting food on their kitchen table. No one should ever be forced to choose between feeding their family and obtaining critical medical care. The Judiciary Committee passed several bipartisan bills targeting abusive tactics that delay access to cheaper generic alternatives for prescription drugs and examined the effects of consolidation and anticompetitive conduct in health care markets, including prescription drug markets.

Committee Work

H.R. 965, the “Creating and Restoring Equal Access to Equivalent Samples (CREASES) Act of 2019” [Marked Up, Passed House, LAW]*

H.R. 2374, the “Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act” [Marked Up]

H.R. 2375, the “Preserve Access to Affordable Generics and Biosimilars Act” [Marked Up]

H.R. 2376, the “Prescription Pricing for the People Act of 2019” [Marked Up]

H.R. 3991, the “Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019” [Marked Up]

H.R. 5133, the “Affordable Prescriptions for Patients Through Promoting Competition Act of 2019” [Marked Up]

Hearing: Diagnosing the Problem: Exploring the Effects of Consolidation and Anticompetitive Conduct in Health Care Markets

Spotlight: H.R. 965, the “Creating and Restoring Equal Access to Equivalent Samples (CREASES) Act of 2019,” would crack down on gamesmanship by branded drug companies that keep generic drug companies from developing cheaper alternatives. It is estimated that the bill, which was signed into law as part of the end of year appropriations bill, will save consumers at least $3.7 billion over ten years.